Current role
Biotechnology · Healthcare
Board Member
2023-01-01–present
George Scangos
Board Member
Voyager Therapeutics, Inc. (VYGR)Equibles does not estimate personal net worth.
Get an email with a short summary when Voyager Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get VYGR alertsAbout George Scangos
George Scangos is recorded as Board Member at Voyager Therapeutics, Inc. (VYGR) since January 1, 2023. The newest filing on record that lists George Scangos as Board Member at Voyager Therapeutics, Inc. (VYGR) is dated April 28, 2026. George Scangos was last confirmed as Board Member at Vir Biotechnology, Inc. (VIR) in a filing dated April 7, 2022. Voyager Therapeutics, Inc. reported in an 8-K filed May 9, 2023 that George Scangos was appointed director of the Company and as a member of the Science and Technology Committee of the Board, effective May 9, 2023. Vir Biotechnology, Inc. reported in an 8-K filed January 25, 2023 that George Scangos retired as Chief Executive Officer and President, effective April 3, 2023. The proxy statement of Vir Biotechnology, Inc. reports total compensation of $338,200 for George Scangos in fiscal 2023, including a base salary of $325,000. Disclosed compensation is on record for 6 fiscal years. Voyager Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Voyager Therapeutics, Inc. includes Alfred Sandrock (CEO and Board Member), Alfred Sandrock, M.D., Ph.D. (CEO and Board Member), Michael Higgins (CEO and Board Member) and 7 others.
“On May 6, 2023, the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed George Scangos, Ph.D. as a director of the Company and as a member of the Science and Technology Committee of the Board, effective May 9, 2023.”
“On January 19, 2023, George Scangos, Ph.D., notified the Board of Directors (the "Board") of Vir Biotechnology, Inc. (the "Company") of his decision to retire as Chief Executive Officer and President effective as of the Effective Date (as defined below).”
Affiliation history
-
Current
2023-01-01–present
Last confirmed April 28, 2026
-
2017-01-01–2022-04-07
Last confirmed by a filing; no departure on record
Company network
Biotechnology · Healthcare
Board Member
Since 2017-01-01, last confirmed 2022-04-07
Leadership on record at Voyager Therapeutics, Inc.
- Alfred Sandrock CEO, Board Member
- Alfred Sandrock, M.D., Ph.D. CEO, Board Member
- Michael Higgins CEO, Board Member
- Nathan Jorgensen, Ph.D., M.B.A. CFO
- Peter P. Pfreundschuh CFO
- Robin Swartz CFO, COO
- Glenn Pierce, M.D., Ph.D. CTO, Board Member
- Gregory Shiferman General Counsel
- Amy Quinlan Chief Accounting Officer
- Julie Burek Chief Accounting Officer
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Vir Biotechnology, Inc. (VIR) | Former President and Chief Executive Officer | $325,000 | $338,200 |
| 2022 | Vir Biotechnology, Inc. (VIR) | Former President and Chief Executive Officer | $638,333 | $7,479,898 |
| 2021 | Vir Biotechnology, Inc. (VIR) | Former President and Chief Executive Officer | $575,000 | $20,682,838 |
| 2020 | Vir Biotechnology, Inc. (VIR) | Former President and Chief Executive Officer | $544,583 | $994,883 |
| 2019 | Vir Biotechnology, Inc. (VIR) | President and Chief Executive Officer | $514,583 | $3,944,607 |
| 2018 | Vir Biotechnology, Inc. (VIR) | President and Chief Executive Officer | $512,019 | $783,019 |